Similarly, serum Gal-9 levels were positively correlated with FABP1 levels in our RA patients, and serum Gal-9 and FABP1 significantly declined in patients after 12 months of DMARDs therapy, paralleling the decrease in RA disease activity. The gene discussed is FABP1; the disease is rheumatoid arthritis.